Facebook Defeats Patent Claims Over News Feed and Timeline Features

Mirror Worlds Techs., LLC v. Meta Platforms, Inc Authored by: Jeremy J. Gustrowsky A recent Federal Circuit decision has closed the book on a long-running patent dispute between Mirror Worlds Technologies, LLC and Meta Platforms, Inc. (formerly Facebook, Inc.), with…

Read More

Cancer Test Patent Dispute Leads to Preliminary Injunction Against NeoGenomics

Natera, Inc. v. NeoGenomics Labs., Inc Authored by: Jeremy J. Gustrowsky A recent decision from the Federal Circuit highlights the importance of patent rights in the competitive world of cancer diagnostics. Natera, Inc., a company specializing in oncology testing, secured…

Read More

When Is a “Single Action” Not Enough? Federal Circuit Clarifies Doctrine of Equivalents Proof Requirements

Nexstep, Inc. v. Comcast Cable Commc’ns, LLC Authored by: Jeremy J. Gustrowsky A recent Federal Circuit decision has clarified the high bar for proving patent infringement under the doctrine of equivalents, especially when the technology at issue seems simple. The…

Read More

Federal Circuit Clarifies Written Description for Drug Combination Patents

Novartis Pharms. Corp. v. Torrent Pharma Inc. (In re Entresto (Sacubitril_Valsartan)) Authored by: Jeremy J. Gustrowsky A recent Federal Circuit decision has important implications for pharmaceutical patents covering drug combinations, especially when new forms of those combinations are discovered after…

Read More

Army’s $245 Million Special Forces Training Contract Survives Bid Protest After Federal Circuit Review

Oak Grove Techs., LLC v. United States Authored by: Jeremy J. Gustrowsky A recent Federal Circuit decision highlights the complex rules that govern government contract awards, especially when multiple companies challenge the process. The dispute centered on a $245 million…

Read More

Expert Testimony in Patent Cases: Timing of Experience Doesn’t Disqualify

Osseo Imaging, LLC v. Planmeca USA Inc Authored by: Jeremy J. Gustrowsky A recent decision from the Federal Circuit clarifies an important point about expert testimony in patent cases: an expert does not need to have been a “person of…

Read More

Patent Board Faulted for Failing to Explain Its Reasoning in Network Security Patent Challenge

Palo Alto Networks, Inc. v. Centripetal Networks, LLC Authored by: Jeremy J. Gustrowsky In a recent decision, the Federal Circuit vacated and remanded a Patent Trial and Appeal Board (PTAB) ruling after finding that the Board failed to adequately explain…

Read More

Federal Circuit Revives ParkerVision’s Patent Claims Against Qualcomm Over Wireless Chip Technology

Parkervision, Inc. v. Qualcomm Inc Authored by: Jeremy J. Gustrowsky A recent decision by the Federal Circuit has breathed new life into ParkerVision’s long-running patent dispute with Qualcomm over wireless communication technology. The court found that the lower district court…

Read More

Patent Appeal Dismissed: No Standing Without Real Threat of Infringement

Platinum Optics Tech. Inc. v. Viavi Sols. Inc. Authored by: Jeremy J. Gustrowsky A recent decision from the Federal Circuit highlights the importance of having a real and immediate threat of harm before a company can appeal a Patent Trial…

Read More

Patent Damages and Willfulness Standards Tightened in Food Machinery Patent Dispute

Provisur Techs., Inc. v. Weber, Inc Authored by: Jeremy J. Gustrowsky A recent appellate decision has clarified several important issues in patent law, particularly around proving infringement, willful infringement, and calculating damages. The case involved Provisur Technologies, Inc., which owns…

Read More

Court Upholds $25,000 Sanction for Repeatedly Filing Meritless Patent Lawsuits

PS Prods. Inc. v. Panther Trading Co. In Authored by: Jeremy J. Gustrowsky A recent Federal Circuit decision highlights the risks for companies that repeatedly file weak or baseless patent lawsuits. In this case, PS Products, Inc. (PSP) sued Panther…

Read More

Regeneron Wins Key Injunction to Block EYLEA® Biosimilar Launch

Regeneron Pharms., Inc. v. Mylan Pharms. Inc Authored by: Jeremy J. Gustrowsky In a significant win for Regeneron Pharmaceuticals, the Federal Circuit affirmed a preliminary injunction that blocks Samsung Bioepis (SB) from launching its EYLEA® biosimilar in the United States.…

Read More